Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy

Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy

The advent of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy, especially the triple therapy combining the drugs elexacaftor, tezacaftor, ivacaftor (ETI), has significantly changed the course of the disease in people with cystic fibrosis (pwCF). ETI, which is approved fo...

Full description

Saved in:
Bibliographic Details
Main Authors: Justyna Milczewska, Zulfiya Syunyaeva, Aleksandra Żabińska-Jaroń, Dorota Sands, Stephanie Thee
Format: Article
Language:English
Published: European Respiratory Society 2024-12-01
Series:European Respiratory Review
Online Access:http://err.ersjournals.com/content/33/174/240068.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items